Commentary|Articles|November 19, 2026

Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus

Listen
0:00 / 0:00

J&J’s separations of Kenvue and DePuy Synthes test whether Innovative Medicine and MedTech create more value together than apart.

For more than a century, Johnson & Johnson (J&J) built its competitive position through diversification. Pharmaceuticals, medical devices, and consumer health businesses provided distinct revenue streams, shared financial resources, and resilience across market cycles.

That structure helped establish one of the most enduring corporations in health care. Today, J&J is changing the boundaries of the enterprise while preserving two substantial businesses: Innovative Medicine and MedTech.

“For J&J and other pharmaceutical companies, three practical tests can guide decisions about corporate ownership. The capability test asks whether common ownership improves innovation productivity through expertise, infrastructure, or coordination that individual businesses are not able to achieve on their own.”

The 2023 separation of consumer health company Kenvue, the proposed separation of DePuy Synthes, and continued investments in surgical robotics and innovative medicines suggest a deliberate reassessment of corporate ownership. J&J is redefining which businesses benefit from belonging together.

The question is consequential: Which businesses create more value under J&J's ownership than they could independently? Answering it requires evidence about organizational capabilities, investment returns, and patient outcomes rather than assumptions about the virtues of size or focus.

Why is Johnson & Johnson’s Strategy Shifting Away from Diversification?

Diversification can smooth earnings, support investments through uncertain development cycles, and spread risk across technologies and customers. It can also create shared capabilities in clinical research, regulatory affairs, manufacturing, and international commercialization.

These advantages matter when a corporate parent contributes resources that operating businesses cannot obtain as effectively elsewhere. Yet pharmaceutical and medical technology businesses have different innovation systems.

Because medicines, surgical technologies, and consumer health products rely on distinct innovation systems (biological discovery and regulatory approval, engineering and hospital adoption, and brands and retail distribution, respectively), management must demonstrate where shared ownership improves performance. Financial flexibility alone is an incomplete justification: independent companies can raise capital, partner, and purchase specialized services.

A stronger case for diversification rests on distinctive capabilities that improve innovation and commercialization across businesses. This question has become more pressing as J&J manages pharmaceutical exclusivity losses.

In the third quarter of 2026, the company reported $25.4 billion in sales, representing 5.9% year-over-year growth despite continued declines in Stelara (ustekinumab) revenue from biosimilar competition.1 The performance demonstrates portfolio resilience, although it does not establish that combining Innovative Medicine and MedTech caused that resilience.

What Businesses Did Johnson & Johnson Divest or Spin Off?

After J&J completed the separation of Kenvue, the consumer health company focused on pursuing its own investment and operating priorities. J&J retained Innovative Medicine and MedTech, businesses with substantial scientific, clinical, and technological requirements.

The separation clarified the corporation's priorities but left an important question about the value of combining its remaining operations. The proposed separation of DePuy Synthes extends this reassessment.

Announced in October 2025, the plan would establish a more independent orthopedics business while concentrating J&J's MedTech investments in other markets.3 In October 2026, management indicated that the transaction remained on track for mid-2027, with a spin-off emerging as the preferred structure.

J&J had not completed the separation as of November 2026. Orthopedics remains clinically important, with established implants, instruments, and digital surgical technologies.

Readers should not interpret its potential independence as evidence that the business lacks innovation. The strategic issue is whether dedicated capital allocation and management attention would generate greater value outside J&J than the corporate parent can create through continued ownership.

Restructuring also carries costs. J&J reported $194 million in expenses during the first nine months of 2026 under a separate Surgery franchise restructuring program, with total project costs expected to reach ~$600 million.1

These expenses should not be confused with the costs of separating DePuy Synthes, but they illustrate that strategic focus requires resources and operational disruption. Expected improvements must ultimately justify the investments needed to achieve them.

How Does Surgical Robotics Reveal What J&J Wants to Own?

J&J's investment in the OTTAVA robotic surgical system offers a revealing contrast. The system received FDA De Novo marketing authorization in July 2026 for specified general surgical procedures.

Its table-integrated design and connection to J&J's digital surgery capabilities create an opportunity to combine robotics with instruments, energy devices, and procedural expertise already present in the company's surgery business. Yet DePuy Synthes also has robotic technology, including the VELYS platform.

J&J is making a selective choice about which procedural ecosystems management believes can benefit most from shared investment and complementary capabilities. OTTAVA faces established competitors, particularly Intuitive Surgical, whose installed systems, surgeon training infrastructure, and recurring instrument revenues create substantial competitive advantages.

J&J must demonstrate meaningful clinical, operational, or economic differentiation to support adoption. OTTAVA's authorization establishes a regulatory milestone rather than a proven commercial advantage.

Hospital adoption, surgeon training, utilization, clinical outcomes, recurring revenues, and development costs determine whether the platform earns attractive returns. The contrast with DePuy Synthes provides a test of whether J&J's portfolio choices reflect genuine advantages from common ownership.

Acquisitions Test the Same Ownership Logic

The November 16, 2026, agreement to acquire Ollin Biosciences extends J&J's strategy into an adjacent therapeutic market. The announced consideration comprises $2.2 billion upfront and up to $1.125 billion in regulatory and commercial milestones.

Ollin's lead asset, OLN324, is an investigational bispecific antibody in Phase III development for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. J&J separately announced a $750 million development-financing arrangement with Blackstone Life Sciences, carrying contingent payments and royalties.

That financing may provide flexibility, but its obligations remain relevant to the acquisition's economics. J&J has established capabilities in vision care and ophthalmic technologies.

Retinal medicines represent a potential adjacency, although experience in surgical and optical products does not automatically translate into pharmaceutical development or commercialization advantage. The corporate question is whether J&J can accelerate clinical development, improve market access, or create complementary value that Ollin could not achieve as effectively through other ownership or partnership arrangements.

The agreement demonstrates management's investment priorities. OLN324's clinical differentiation, regulatory prospects, commercial uptake, and financial returns remain uncertain. The purchase price alone cannot establish that J&J is the best owner.

What Holds Innovative Medicine and MedTech Together?

J&J reported ~$94.2 billion in 2025 sales, with about $60.4 billion from Innovative Medicine and $33.8 billion from MedTech.4 These businesses remain a diversified enterprise even after Kenvue's separation and the proposed orthopedics transaction.

Their continued combination deserves the same scrutiny applied to divestitures. J&J may benefit from financial flexibility, clinical evidence expertise, global regulatory infrastructure, and relationships across health care systems.

Some capabilities may support both segments, but J&J should demonstrate the overlap rather than presume it. A hospital buying robotic equipment evaluates capital costs, training, and procedural efficiency; a payer assessing a new medicine evaluates clinical evidence, comparative effectiveness, and price.

Understanding both environments may offer advantages, but management must identify where that knowledge translates into measurable performance. Capital allocation provides a practical test.

Every dollar directed toward robotics, retinal therapeutics, or an established pharmaceutical franchise carries an opportunity cost. Management should assess returns against development risk, acquisition premiums, integration requirements, and plausible alternatives.

Leadership and the Discipline of Corporate Ownership

Under CEO Joaquin Duato, J&J has pursued a more selective approach to corporate ownership. The company has taken actions to build on capabilities and strategic commitments developed over multiple leadership periods.

Duato's central challenge is to establish a consistent framework for allocating capital, evaluating corporate ownership, and measuring the value created by businesses J&J retains. The durability of this strategy depends on whether those principles become embedded in organizational decision-making and remain effective beyond individual executives.

Patient Value and the Next Strategic Test

The consequences extend beyond shareholders. OTTAVA could improve surgical workflows, but clinical and economic benefits require evidence from real-world use.

OLN324 could expand retinal treatment options, but its value depends on demonstrated outcomes, treatment burden, safety, and access. A separated orthopedics business must still support innovation, reliable supply, and patient care.

For J&J and other pharmaceutical companies, three practical tests can guide decisions about corporate ownership. The capability test asks whether common ownership improves innovation productivity through expertise, infrastructure, or coordination that individual businesses are not able to achieve on their own.

The capital allocation test examines whether the corporation generates attractive risk-adjusted returns after accounting for acquisition costs, restructuring expenses, and alternative investments. The patient-value test evaluates whether shared ownership accelerates clinically meaningful innovation, improves outcomes, or expands appropriate access.

These tests require evidence over time: pipeline progress, adoption, operating performance, capital efficiency, and patient results. They also require management to reconsider ownership when circumstances change.

J&J's transformation offers a broader lesson for pharmaceutical companies confronting patent expirations, technological change, and rising development costs. Corporate boundaries should reflect the areas in which an organization can contribute distinctive capabilities.

Focus has value when it improves those contributions; diversification has value when the benefits of combining businesses exceed the costs. J&J's enduring competitive advantage depends on its ability to create greater value from its chosen businesses under common ownership than those businesses could achieve independently.

References

  1. Johnson & Johnson. Quarterly report on Form 10-Q for the fiscal quarter ended September 27, 2026. 2026.
  2. Johnson & Johnson. Johnson & Johnson announces final results of exchange offer and finalizes separation of Kenvue Inc. Press release. August 23, 2023.
  3. Johnson & Johnson. Johnson & Johnson announces intent to separate its orthopedics business. Press release. October 14, 2025.
  4. Johnson & Johnson. Johnson & Johnson reports Q4 and full-year 2025 results. Press release. January 21, 2026.
  5. US Food and Drug Administration. De Novo classification order DEN250068: OTTAVA robotic surgical system. July 21, 2026.
  6. Johnson & Johnson. Johnson & Johnson receives FDA market authorization in the US for its OTTAVA robotic surgical system. Press release. July 22, 2026.
  7. Johnson & Johnson. Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology. Press release. November 16, 2026.


Related to this article